Contract manufacturing and outsourcing agreement with COSMO BIO COMPANY,LIMITED for peptide synthesis and packaging of services
First written in FY2019-Q3. 11 of 12 entries say "Restated". Latest entry: FY2026-H1.
1 other company's latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「Based on the results obtained from neoantigen analysis, peptide synthesis is outsourced to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. A service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens is packaged and provided.」
The company continues to outsource peptide synthesis to COSMO BIO COMPANY,LIMITED and package neoantigen analysis together with the provision of synthesized peptides. - FY2023-Q3RestatedAnnual report
「Based on the results obtained from neoantigen analysis, peptide synthesis is outsourced to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. A service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens is packaged and provided.」
The company continues to outsource peptide synthesis to COSMO BIO COMPANY,LIMITED and package neoantigen analysis together with the provision of synthesized peptides. - FY2023-Q1RestatedAnnual report
「Based on the results obtained from neoantigen analysis, peptide synthesis is outsourced to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. A service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens is packaged and provided.」
The company continues to outsource peptide synthesis to COSMO BIO COMPANY,LIMITED and package neoantigen analysis together with the provision of synthesized peptides. - FY2022-Q3RestatedAnnual report
「Based on the results obtained from CPM's neoantigen analysis, CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
The company continues to pursue its policy of outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging neoantigen analysis together with the provision of synthesized peptides. - FY2022-Q1RestatedAnnual report
「Based on the results obtained from CPM's neoantigen analysis, CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
The company continues to pursue its policy of outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging neoantigen analysis together with the provision of synthesized peptides. - FY2021-Q3RestatedAnnual report
「Based on the results obtained from CPM's neoantigen analysis, CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
The company continues to pursue its policy of outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging neoantigen analysis together with the provision of synthesized peptides. - FY2021-Q2RestatedAnnual report
「CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
The company continues to pursue its policy of outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging neoantigen analysis together with the provision of synthesized peptides. - FY2021-Q1RestatedAnnual report
「CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
The company continues to pursue its policy of outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging neoantigen analysis together with the provision of synthesized peptides. - FY2020-Q3RestatedAnnual report
「CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
The company continues to pursue its policy of outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging neoantigen analysis together with the provision of synthesized peptides. - FY2020-Q2RestatedAnnual report
「CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
The company continues to pursue its policy of outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging neoantigen analysis together with the provision of synthesized peptides. - FY2020-Q1RestatedAnnual report
「Based on the results obtained from CPM's neoantigen analysis, CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
The company continues to pursue its policy of outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging neoantigen analysis together with the provision of synthesized peptides. - FY2019-Q3First statedAnnual report
「CPM entered into an agreement with COSMO BIO COMPANY,LIMITED for the outsourcing and contracting of peptide synthesis for cancer immunotherapy. Based on the results obtained from CPM's neoantigen analysis, CPM outsources peptide synthesis to COSMO BIO COMPANY,LIMITED to shorten the peptide synthesis period for cancer immunotherapy. CPM will also package and provide a service that adds the provision by CPM to medical and research institutions of peptides synthesized by COSMO BIO COMPANY,LIMITED to CPM's neoantigen analysis service using cancer specimens.」
CPM began outsourcing peptide synthesis to COSMO BIO COMPANY,LIMITED and packaging a service that combines neoantigen analysis with the provision of synthesized peptides.